Liposomal Doxorubicin (Lipo-Dox) in Patients With Brain Metastasis From Breast Cancer

Inclusion Criteria: * Histologically or cytologically proved breast cancer * Relapse/recurrent brain metastasis progression after brain radiotherapy * Presence of brain measurable disease which is defined as at least one brain lesion that can be measured in at least 1 dimension as ³ 20 mm with magnetic resonance image (MRI) * Prior chemotherapy or hormone therapy for metastatic breast cancer is allowed * Performance status of ECOG 0, 1, 2 * With normal left ventricular ejection fraction and normal ventricular contractility * Age 21 years or older * Life expectancy equal or longer than 3 months * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Prior anthracycline-containing chemotherapy with cumulative dose exceed 400mg/m2 doxorubicin or 750 mg/m2 Epirubicin * Surgery , radiotherapy, hormonal therapy or chemotherapy within 4 weeks prior to entering the study * Prior liposomal doxorubicin treatment * Concurrent chemotherapy, radiotherapy, hormonal therapy, or other investigational drug except non-disease related conditions (e.g. insulin for diabetes) during study period * Other malignancy with exception of curative treated non-melanoma skin cancer or cervical carcinoma in situ within 5 years prior to entering the study * Brain metastases defined as meninges metastases * Presence of serious concomitant illness which might be aggravated by study medication: * Uncontrolled infection (active serious infections that are not controlled by antibiotics) * Active cardiac disease e.g. decompensate myocardial infarction within the 6-month period preceding entry into the study. * History of ventricular arrhythmia or congestive heart failure. * Presence of abnormal left ventricular ejection fraction * Hematopoietic function as defined below: * Hemoglobin\<10g/dl * ANC\< 1,500/uL * Platelets\<100,000/uL * Organ function as defined below: * Total bilirubin \>1.5 × ULN * ALT / AST\>3 × ULN (\>5.0 x ULN if hepatic metastasis) * Creatinine \>1.5 × ULN * Mental status is not fit for clinical trial * Pregnant or breast feeding women, or women of child-bearing potential unless using a reliable and appropriate contraceptive method